ADVANCES IN MANAGING CUSHING S DISEASE. Rosario Pivonello Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
|
|
- Bertha Eaton
- 5 years ago
- Views:
Transcription
1 ADVANCES IN MANAGING CUSHING S DISEASE Rosario Pivonello Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
2 Patients with persistent Cushing s disease have higher morbidity and mortality Study Lindholm (n=73) Hammer (n=289) Dekkers (n=74) Clayton (n=60) Overall (I 2 =67.2%, P=0.027) Persistent disease Estimated SMR (95% CI) 5.06 (2.27, 11.26) 2.80 (1.33, 5.87) 4.38 (1.82, 10.52) (6.66, 38.44) 5.50 (2.69, 11.26) Lindholm (n=73) Hammer (n=289) Dekkers (n=74) Clayton (n=60) Overall (I 2 =82.2%, P=0.001) Remission 0.31 (0.14, 0.69) 1.18 (0.56, 2.48) 1.80 (0.75, 4.32) 3.30 (1.37, 7.93) 1.20 (0.45, 3.18) Clayton RN et al. J Clin Endocrinol Metab 2011;96: Note: Weights are from random effects analysis
3 Hypercortisolism leads to reduced HRQoL Functional impairments in HRQoL are directly attributable to the effects of prolonged hypercortisolism Most patients with Cushing s disease have physical and psychological symptoms which may lead to impaired HRQoL However, studies with longer follow-up suggest that prolonged exposure to high levels of cortisol may cause persistent deleterious effects on HRQoL Feelders RA et al. Eur J Endocrinol 2012;167:
4 Prolonged exposure to cortisol excess leads to worse outcome The mean time span between initial physician consultation and final diagnosis of Cushing s disease is 2 5 years 1 6 Duration of hypercortisolism pre-cure has a significant impact on the severity and extent of co-morbidities post-cure Mortality Early diagnosis and prompt treatment are therefore needed Reversibility of complications Duration of hypercortisolism (years) 1 Flitsch J et al. Exp Clin Endocrinol Diabetes 2000;108: ; 2 Martínez Ruiz M et al. An Pediatr (Barc) 2003;59: ; 3 Etxabe J & Vazquez JA. Clin Endocrinol 1994;40: ; 4 Daly AF et al. J Clin Endocrinol Metab 2006;91: ; 5 Bolland MJ et al. Clin Endocrinol (Oxf) 2011;75: ; 6 Valassi E et al. Eur J Endocrinol 2011;165:
5 Treatment Goals for Cushing s Disease Normalization of cortisol levels with minimal morbidity Removal of tumor mass and/or stabilization of tumor growth Preservation of pituitary function Reversal of morbidity and mortality Improvement of quality of life Long-term control without recurrence Biller et al. J Clin Endocrinol Metab. 2008;93:
6 Transsphenoidal surgery is first-line therapy in Cushing s disease However Not always successful - Initial success rate 68 98% in patients with a microadenoma 1,2 - Remission rates lower (<65%) in patients with a macroadenoma 1 Patients are not always controlled in the long term - Relapse rate is 2 26% (after months) 2 Not always feasible 1 Biller BMK et al. J Clin Endocrinol Metab 2008;93: ; 2 Tritos NA et al. Nat Rev Endocrinol 2011;104:
7 Hypopituitarism following first surgery Hypopituitarism has been reported in 1 22% of patients following surgery for Cushing s disease 1,2 Patients with hypopituitarism have decreased HRQoL 3 and approximately 2-fold higher mortality than the general population 4,5 Hypopituitarism requires chronic hormone replacement therapy 1 Sudhakar N et al. Br J Neurosurg 2004;18: ; 2 Roelfsema F et al. Pituitary 2012;15:71 83; 3 van Aken MO et al. J Clin Endocrinol Metab 2005;90: ; 4 Bates AS et al. J Clin Endocrinol Metab 1996;81: ; 5 Tomlinson JW et al. Lancet 2001;357:
8 Current second-line therapies in Cushing s disease Patients with persistent disease after surgery Repeat surgery Radiation therapy Medical therapy Bilateral adrenalectomy Biller BMK et al. J Clin Endocrinol Metab 2008;93:
9 Repeat pituitary surgery Repeat surgery 1,2 Potentially curative Pituitary directed Limitations Risk of cerebrospinal fluid leakage Lower success rate (37 73%) with subsequent surgery for patients in specialized centers 3,4 Hypopituitarism is more common after subsequent surgery Rates of 50% 2 compared with 1 22% for patients following first surgery 5 1 Biller BMK et al. BMC Endocr Disord 2010;10:10; 2 Biller BMK et al. J Clin Endocrinol Metab 2008;93: ; 3 Friedman RB et al. J Neurosurg 1989;71: ; 4 Benveniste RJ et al. J Neurosurg 2005;102: ; 5 Sudhakar N et al. Br J Neurosurg 2004;18:
10 Bilateral adrenalectomy Bilateral adrenalectomy Involves complete removal of both adrenal glands 1 Provides immediate control of hypercortisolism 1 Procedure has 84 91% success rate 2,3 Limitations Results in permanent hypoadrenalism requiring lifelong glucocorticoid and mineralocorticoid replacement 1 Risk of developing Nelson s syndrome (rapid enlargement of corticotroph adenoma) 4 1 Biller BMK et al. BMC Endocr Disord 2010;10:10; 2 Sonino N et al. J Clin Endocrinol Metab 1996;81: ; 3 Chow JT et al. Clin Endocrinol (Oxf) 2008;68: ; 4 Assié G et al. J Clin Endocrnol Metab 2007;92:
11 Radiation therapy for persistent Cushing s disease Radiation therapy Stereotactic radiotherapy requires specialized team and visible tumor (by MRI) Achieves disease control in 50 60% of patients 1 Delayed response, control is seen after 3 5 years 2,3 Limitations Associated with a high risk of hypopituitarism 4 Risk of second brain tumor formation, in the range of 1 2% Increased risk of cerebrovascular death 1 Biller BMK et al. J Clin Endocrinol Metab 2008;93: ; 2 Rim CH et al. Radiation Oncol J 2012;29: ; 3 Castinetti F et al. Eur J Endocrinol 2007;156:91 98; 4 Devin JK et al. Stereotact Funct Neurosurg 2004;
12 Medical Therapy: Indications Severe complications of hypercortisolism Pre-treatment before pituitary surgery Post-treatment after unsuccessful surgery Bridging therapy before, during and after radiation Primary medical therapy (contraindication for surgery or refusal of surgery)
13 Potential Targets for Medical Therapy in Cushing s Disease Pituitary gland CRH Pasireotide Cabergoline Adrenal glands Ketoconazole Metyrapone Mitotane LCI699 ACTH Cortisol Mifepristone Glucocorticoid receptors
14 Adrenal-directed medical therapy Steroidogenesis inhibitors Ketoconazole, mitotane, metyrapone, etomidate Reduce cortisol levels via inhibition of steroid synthesis in the adrenal gland Can be used as a palliative treatment Between administration and effect of radiotherapy To lower cortisol levels in patients preparing for surgery Used for long-term management of disease Do not target the underlying corticotroph tumor or restore normal HPA secretory dynamics (ie non-curative) Safety concerns Biller BMK et al. BMC Endocr Disord 2010;10:10
15 Ketoconazole monotherapy ( mg/day) Retrospective study of 38 patients with active disease (17 had previous surgery) 17 (45%) had normalized UFC; mean follow-up of 23 months Treatment stopped in first week in five patients (13%) due to clinical intolerance (GI symptoms) or biological intolerance (elevated liver enzymes) AEs included a moderate (<3xULN ) increase in γ-gt (8%), nausea and diarrhea (5%), aspartate aminotransferase/alanine aminotransferase 8xULN (3%) Escape: 15% 1 Castinetti F et al. Eur J Endocrinol 2008;158:91 99;
16 Cortisol-receptor-targeted medical therapy Mifepristone Blocks the action of cortisol by binding to the GR-II (cortisol) receptor 4-fold higher affinity than dexamethasone Glucocorticoid receptor antagonist 18-fold higher affinity than cortisol Does not target the underlying corticotroph tumor or restore normal HPA secretory dynamics (ie non-curative) Received FDA approval (Corcept Therapeutics; Korlym ) for control of hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing s syndrome who have type 2 diabetes/glucose intolerance and have not responded to, or are not candidates for, surgery
17 Mifepristone Phase III Trial Design 24-week multicenter, open-label trial of mifepristone mg/day in patients with Cushing s syndrome who had failed standard therapy At baseline, 43 patients had Cushing s disease, 4 had ectopic ACTH secretion, and 3 had adrenal cancer 2 groups of patients were enrolled Patients with glucose intolerance or diabetes (n = 29) Patients with hypertension (n = 21) Screening 42 days Dose escalation until week week treatment n = 84 screened Day 1 Week 6 Week 10 Week 16 Week 24 n = 50 enrolled n = 34 completed Fleseriu et al. Endocr Rev. 2011;32:OR09-5.
18 Mifepristone Phase III Trial: Efficacy Results Primary efficacy analysis group: patients who completed 30 days of mifepristone therapy Response in the primary endpoint was defined as Glucose-intolerant group: 25% improvement in glucose tolerance at 24 weeks compared with baseline Hypertension group: 5 mmhg improvement in diastolic blood pressure at 24 weeks compared with baseline Glucose-intolerant group (n=25) Hypertension group (n=21) Response rate 60% (15/25 patients) 38% (8/21 patients) 95% CI Lower limit 95% CI = 41.7%; P < Lower limit 95% CI = 21%; P value not reported Definition of response: lower bound of the 95% CI for group response rates >20%. Fleseriu et al. Endocr Rev. 2011;32:OR09-5.
19 Mifepristone Phase III Trial Results: Improvement in Signs and Symptoms At week 24, improvements were seen in body weight, waist circumference, insulin resistance, cushingoid appearance, depression, cognition, and HRQoL Change from baseline (%) Decrease in weight with treatment D7 D14 D28 W6 W8 W10 W12 W16 W20 W24/ ET Baseline 99.5 ± 4.4 kg (n=46) 5.7 ± 1.5% P<0.001 vs baseline Baseline (cm) Mean change from baseline (cm) C-DM (N=19) Decrease in waist circumference *P<0.001 vs baseline C-HT (N=13) Females * Overall (N=32) C-DM (N=6) *P<0.001 vs baseline C-HT (N=8) Males * Overall (N=14) Fleseriu et al. Endocr Rev. 2011;32:OR09-5.
20 Mifepristone Phase III Trial: Safety 88% of patients experienced a treatment-related AE 16 patients had a serious AE 7 withdrew due to an AE 2 patients died during the study Half of women had an increase in endometrial thickness 2 patients had adrenal insufficiency reported as an AE 3 patients had severe hypokalemia (K 2.5) The treatment was associated with an increase in ACTH UFC Morning serum cortisol Late-night salivary cortisol Fleseriu et al. Endocr Rev. 2011;32:OR09-5.
21 Pituitary-directed medical therapies for Cushing s disease Despite initial promise, a routine clinical role has not been found for: PPAR-ү agonists such as rosiglitazone 1 Dopamine agonists Cabergoline may be effective in a subset of patients; 2 more trials needed Somatostatin analogues Octreotide and lanreotide are ineffective in Cushing s disease Pasireotide, a multireceptor-targeted somatostatin analogue, has demonstrated efficacy 1 Pecori GF et al. Clin Endocrinol (Oxf) 2006;64: ; 2 Pivonello R et al. J Clin Endocrinol Metab 2009;94:
22 Cabergoline is an option for some patients with Cushing s disease Potent dopamine type 2 (D2) receptor agonist Approximately 80% of ACTH-secreting adenomas express the dopamine D2 receptor 1 D2 receptor might not be greatly downregulated (similar to the resilience of sst 5 ) in the presence of glucocorticoids 2 O NH N N Small studies (n=20 30) have demonstrated the efficacy of cabergoline in a subset of patients 1,3 O N H The phenomenon of escape has been described 3 Studies in larger patient populations are required to establish efficacy and safety NH 1 Pivonello R et al. J Clin Endocrinol Metab 2004;89: ; 2 de Bruin C et al. J Mol Endocrinol 2009;42:47 56; 3 Godbout A et al. Eur J Endocrinol 2010;163: sst, somatostatin subtype receptor
23 Prospective study of cabergoline in Cushing s disease (n=20) Short-term (3 months) efficacy (75%): Eight (40%) partial and seven (35%) full responders; five (25%) non-responders Escape from response occurred after months: Three patients with normalized UFC; two partially responsive patients Patients discontinued treatment Urinary cortisol (µg/day) Patient no Baseline 3 months % were in full remission after 24 months with a median dose of 3.5 mg/week Baseline months Patients with 7 24-month follow-up Patients with month follow-up Number on each arrow indicates the maximal cabergoline dose (mg/week) administered; urinary cortisol levels represent the 200 mean of three different urine collections performed in three different non-consecutive days of the same week 0 Partial response defined as >25% decrease in UFC Patient no Pivonello R et al. J Clin Endocrinol Metab 2009;94: Urinary cortisol (µg/day) 7
24 Retrospective study of cabergoline in Cushing s disease In a study of 30 Canadian/ Argentinian patients: Complete response in 11 patients (36.7%) after average of 4.2 months Partial response in four patients (13.3%); no response in 15 (50.0%) Nine patients (30%) maintained response after a mean of 37 months (up to 60 months) Escape from response observed in two patients after 2 and 5 years No major AEs Complete response defined as normalization of mean UFC Partial response defined as a decrease in UFC to <125% of the upper limit of normal range but without complete normalization of UFC Godbout A et al. Eur J Endocrinol 2012;163: Proportion of UFC ULN (%) Proportion of UFC ULN (%) UFC levels in nine patients with complete response Treatment time (months) UFC levels in two patients with escape from response Cabergoline dose (mg/week) Pt Treatment time (months) Pt 11
25 Ketoconazole in combination with cabergoline After 6 months cabergoline monotherapy (up to 3 mg/ week), 9/12 patients did not adequately respond All 12 patients had undergone previous surgery Addition of ketoconazole (up to 400 mg/day) led to normalized UFC in 6/9 patients (67%) Remaining patients achieved significant reduction in UFC of 44 52% Vilar L et al. Pituitary Jun;13(2):123 9
26 Pasireotide Multireceptor-targeted somatostatin analogue 30-, 5-, and 39-fold higher affinity for sst 1, sst 3 and sst 5 than octreotide, and similar affinity for sst 2 1 N H 2 H N O O O N O N H N H O O H N H N O H N N H O N H 2 Expression of sst 5 predominates in ACTH-secreting pituitary adenomas 2,3 O sst 1, sst 2, and sst 3 are also expressed Broad binding profile means that pasireotide may be an effective treatment for Cushing s disease 1. Bruns et al. Eur J Endocrinol. 2002;146: Strowski et al. Neuroendocrinology. 2002;75: Sharma et al. Mol Endocrinol. 1999;13:82-90.
27 Pasireotide N Engl J Med. 2012;366:
28 Phase III Study: Largest Cushing s Disease Trial 18 countries, 62 sites 329 patients screened 162 patients randomized Argentina, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, 28 Greece, Israel, Italy, Mexico, Poland, Portugal, Spain, Turkey, United States
29 Change in UFC From Baseline to Month 6 in 103 Patients With Baseline and Month-6 UFC Measurements µg bid 900 µg bid * Baseline UFC Month-6 UFC Month-6 UFC ULN UFC (µg/24 h) Individual patients sorted by baseline UFC ULN Median percent UFC change from baseline was 47.9% in both groups Reference line is the upper limit normal UFC, which is 52.5 µg/24 h (145 nmol/24 h).
30 Primary Efficacy Results Response status at 6 months 600 µg bid (n=82) 900 µg bid (n=80) Overall (n=162) *Response, n (%) 12 (14.6) 21 (26.3) 33 (20.4) 95% confidence interval (7.0, 22.3) (16.6, 35.9) (14.2, 26.6) 12-month response, n (%) 11 (13.4) 20 (25.0) 31 (19.1) *NOTE: Responder was a patient with UFC ULN who did not require uptitration Predetermined criterion for the primary efficacy endpoint: lower bound of the 95% CI >15% for either of the dose groups; this was met for the 900-µg group
31 Significant Decrease in Blood Pressure and UFC Systolic blood pressure (SBP) Mean UFC ± SE (µg/24 h) Mean UFC Mean SBP B Diastolic blood pressure (DBP) Mean BP ± SE (mmhg) Significant change from baseline to month 12 was observed for: SBP 6.1 mmhg (95% CI: 9.8, 2.4) Mean UFC Mean DBP B DBP 3.7 mmhg (95% CI: 6.2, 1.2) Month
32 Mean UFC (µg/24 h) Significant Improvement in HRQoL and UFC Measured via Cushing QoL1 Significant (11.1 points) improvement from baseline to month 12 (95% CI: 6.8, 15.5) B Month 1. Webb et al. Eur J Endocrinol. 2008;158: Mean UFC HRQoL score HRQoL score
33 Pasireotide: summary B2305, the large phase III study of pasireotide in Cushing s disease showed Rapid and sustained UFC reduction with pasireotide treatment Decrease in UFC seen from baseline to month 6 in most patients Normalization of UFC in a subset of patients (higher rates for patients with lower baseline UFC) Significant improvement in signs and symptoms seen at 6 months with further improvements by 12 months Pasireotide provides a pituitary-directed medical treatment targeting the underlying cause of the disease
34 Combination Therapy 17 patients Ketoconazole 200 mg TID Feelders et al. N Engl J Med. 2010;362: Stepwise Medical Treatment Pasireotide 250 µg TID Pasireotide 100 µg TID 0 Cabergoline 1.5 mg QOD Time, d Stepwise Medical Treatment B2402 STUDY 80
35 Combination Therapy Disease control with pasireotide alone or in combination in 88% of patients with Cushing s disease Feelders et al. N Engl J Med. 2010;362:
36 LCI699 Is a potent inhibitor of 11β-hydroxylase (CYP11B1), the final step of cortisol synthesis Is a potential new treatment for all forms of Cushing s syndrome, including Cushing s disease This open-label, proof-of-concept study assessed the efficacy and safety/tolerability of LCI699 in adult patients with Cushing s disease over 10 weeks of treatment
37 LCI699: Anticipated Effects in Cushing s Disease (Fasciculata/reticularis) ACTH + - (Glomerulosa) Renin Cholesterol Cholesterol Pregnenolone Volume expansion Pregnenolone Progesterone DOC Progesterone 17-OH progesterone 11-Deoxycortisol LCI699 X CYP11B1 Androgens 11-Deoxycortisol LCI699 DOC X (Corticosterone) (18-OH corticosterone) CYP11B2 (Cortisol) (Aldosterone)
38 Recruitment Status (N = 12) Boston, USA (n = 1) Paris, France (n = 3) Ancona, Italy (n = 2) Cleveland, USA (n = 1) Portland, USA (n = 3) Naples, Italy (n = 2)
39 LCI699: Proof-of-concept study design LCI699 initiated at 4 mg/day (given orally in two divided doses) Dose escalated every 2 weeks until UFC normalized, then maintained until day 70 Followed by a 2-week washout period until day 84 D 64 D 14 D1 D14 D28 D42 D56 D70 D84 Screening Baseline 4 mg 10 mg 20 mg 40 mg 100 mg Washout n=12 enrolled UFC UFC UFC UFC UFC UFC UFC Primary endpoint UFC ULN or 50% decrease from baseline at day 70 Secondary endpoints ACTH, steroid hormone precursors, androgens, body weight, blood pressure, glucose, potassium and sodium levels, AEs Bertagna X et al. J Klin Endokrinol Stoffw 2012;5(Special Issue 3):abst OC04
40 Urinary Cortisol Over Time in All Patients Mean UFC ± SE (fold ULN) 7 LCI699 dose escalation Washout Day All 12 patients achieved the primary endpoint at day 70 11/12 (92%) had normal urinary cortisol at day 70 Urinary cortisol normalized in all 12 patients at least once
41 Changes in Clinical and Laboratory Features During LCI699 Treatment Baseline (n=12) Day 70 (n=12) Change from baseline (n=12) SBP (mmhg) ± ± ± 4.7 DBP (mmhg) 87.9 ± ± ± 3.7 Weight (kg) 96.7 ± ± ± 1.3 Glucose (mg/dl) ± ± ± 11.8 Potassium (meq/l) 4.3 ± ± ± 0.2 Sodium (meq/l) ± ± ± 1.1 Data presented as mean ±SE. SBP, systolic blood pressure; DBP, diastolic blood pressure.
42 Safety of LCI699 All patients experienced at least 1 AE during treatment Most AEs were mild to moderate AEs requiring dose adjustment were consistent with adrenal insufficiency AEs were easily managed with dose reductions Fatigue, nausea, abdominal pain, and infection were the most common AEs 4 patients had hypokalemia (K+ <3.5 meq/l; min 3.1) 3 patients received oral potassium supplementation No dose reductions needed 1 patient had a serious AE Rapid anemia with palpitations and chest pain History of inflammation-related anemia
43 Retinoic acid in Cushing s disease Prospective proof-of-concept study in seven patients with Cushing s disease Evaluated the efficacy and safety of escalating doses of retinoic acid (10 80 mg/day) over 6 12 months of treatment Five patients (71.4%) had 50% decrease/normalization of UFC after 6 months Three patients (42.9%) normalized UFC Changes in ACTH were variable and generally less pronounced Treatment was generally well tolerated Treatment duration Urinary free cortisol (µg/24h) Retinoic acid Pt 1 Retinoic acid Pt 2 Retinoic acid Pt Pretreatment Months 0 Pretreatment Months 0 Pretreatment Months Urinary free cortisol (µg/24h) Retinoic acid Pt Retinoic acid Pt Retinoic acid Pt Retinoic acid Pt 7 0 Pretreatment Months 0 Pretreatment Months 0 Pretreatment 3 6 Months 0 Pretreatment 3 6 Months Pecori Giraldi F et al. J Clin Endocrinol Metab 2012;97: Shaded area represents normal range
44 Conclusions Surgery is first-line treatment, but is associated with high relapse rates and is not a viable option in some patients Repeat pituitary surgery, bilateral adrenalectomy and radiotherapy can result in control of hypercortisolism, but they are associated with variable response rates and significant risks Prior to 2012, medical therapy was used in an off-label manner Ketoconazole is the most commonly used steroidogenesis inhibitors, providing control of cortisol in many patients In small studies, cabergoline induced full remission in 30 40% of patients during 2 5-year follow-up Mifepristone leads to significant clinical and metabolic improvements in patients with Cushing s syndrome and diabetes mellitus during 6 months of treatment Pasireotide is the first approved pituitary-targeted medical therapy to rapidly decrease and normalize UFC and improve signs/symptoms
45 Thanks
TREATMENT OF CUSHING S DISEASE
TREATMENT OF CUSHING S DISEASE Surgery, Radiation, Medication Peter J Snyder, MD Professor of Medicine Disclosures Novartis Research grant Pfizer Consultant Ipsen Research grant Cortendo Research grant
More informationTherapeutic Objectives. Cushing s Disease Surgical Results. Cushing s Disease Surgical Results: Macroadenomas 10/24/2015
Therapeutic Objectives Update on the Management of Lewis S. Blevins, Jr., M.D. Correct the syndrome by lowering daily cortisol secretion to normal Eradicate any tumor that might threaten the health of
More informationI farmaci ad azione surrenalica: METIRAPONE ed OSILODROSTAT
I farmaci ad azione surrenalica: METIRAPONE ed OSILODROSTAT Maria Cristina De Martino Dipartimento di Medicina Clinica e Chirurgia Sezione di Endocrinologia, Università Federico II di Napoli, Italy 1 Treatment
More informationUpdate on Cushing s disease (CD)
Update on Cushing s disease (CD) Beverly MK Biller, MD Professor of Medicine Harvard Medical School Neuroendocrine Clinical Center Massachusetts General Hospital Boston, MA Disclosure of potential relevant
More informationMedical Therapy: Indications
Medical Therapy: Indications Severe complications of hypercortisolism Pre-treatment before pituitary surgery Post-treatment after unsuccessful surgery Bridging therapy before, during and after pituitary
More informationClinical Commissioning Policy Proposition: Pasireotide: An injectable medical therapy for the treatment of Cushing's disease
Clinical Commissioning Policy Proposition: Pasireotide: An injectable medical therapy for the treatment of Cushing's disease Information Reader Box (IRB) to be inserted on inside front cover for documents
More informationTitle: Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas
Author's response to reviews Title: Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas Authors: Beverly MK Biller (bbiller@partners.org)
More informationstone) Policy covered: in patients d): Korlym is enrolled in diabetes or glucose Cushing s syndrome adult patients with treated with metabolic caused
Korlym (mifepris stone) Policy Number: 5.01.545 Origination: 06/2013 Last Review: 05/2014 Next Review: 05/2015 Policy BCBSKC will provide coverage for Korlym when it is determined to be medically necessary
More informationAdvances in Pituitary. Anne Klibanski, M.D. Massachusetts General Hospital Harvard Medical School
Advances in Pituitary Anne Klibanski, M.D. Massachusetts General Hospital Harvard Medical School Pituitary tumor types Gonadotroph (15-40%) Clinically nonfunctioning Visual field loss Hypopituitarism Thyrotroph
More informationmifepristone (Korlym )
mifepristone (Korlym ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ),
More informationULTIMATE BEAUTY OF BIOCHEMISTRY. Dr. Veena Bhaskar S Gowda Dept of Biochemistry 30 th Nov 2017
ULTIMATE BEAUTY OF BIOCHEMISTRY Dr. Veena Bhaskar S Gowda Dept of Biochemistry 30 th Nov 2017 SUSPECTED CASE OF CUSHING S SYNDROME Clinical features Moon face Obesity Hypertension Hunch back Abdominal
More informationPituitary Gland Disorders
Pituitary Gland Disorders 1 2 (GH-RH) (CRH) (TRH) (TRH) (GTRH) (GTRH) 3 Classification of pituitary disorders: 1. Hypersecretory diseases: a. Acromegaly and gigantism: Usually caused by (GH)-secreting
More informationThe endocrine system is made up of a complex group of glands that secrete hormones.
1 10. Endocrinology I MEDCHEM 535 Diagnostic Medicinal Chemistry Endocrinology The endocrine system is made up of a complex group of glands that secrete hormones. These hormones control reproduction, metabolism,
More informationCase Report Monitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing s Disease
Case Reports in Endocrinology Volume 2013, Article ID 735489, 5 pages http://dx.doi.org/10.1155/2013/735489 Case Report Monitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing
More informationProspective, Open Label, Phase 3 Study of Levoketoconazole in Cushing Syndrome (SONICS): Primary Safety and Efficacy Results
Prospective, Open Label, Phase 3 Study of Levoketoconazole in Cushing Syndrome (SONICS): Primary Safety and Efficacy Results Eliza B. Geer Maria Fleseriu, 1 Rosario Pivonello, 2 Atanaska Elenkova, 3 Roberto
More informationCortisol levels. Naturally produced by the adrenal Cortisol
1 + 2 Cortisol levels asleep awake Naturally produced by the adrenal Cortisol Man made tablets, injections, creams & inhalers Cortisone Hydrocortisone Prednisone Prednisolone Betamethasone Methylprednisolone
More informationCUSHING SYNDROME Dr. Muhammad Sarfraz
Indep Rev Jul-Dec 2018;20(7-12) CUSHING SYNDROME Dr. Muhammad Sarfraz IR-655 Abstract: It is defined as clinical condition in which there are increased free circulating glucocorticoides casused by excessive
More informationCHOLESTEROL IS THE PRECURSOR OF STERIOD HORMONES
HORMONES OF ADRENAL CORTEX R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty CHOLESTEROL IS THE PRECURSOR OF STERIOD HORMONES CONVERSION OF CHOLESTROL TO PREGNENOLONE MINERALOCORTICOCOIDES
More informationDiseases of the Adrenal gland
Diseases of the Adrenal gland Adrenal insufficiency Cushing disease vs syndrome Pheochromocytoma Hyperaldostronism What are the layers of the adrenal gland?? And what does each layer produce?? What are
More informationA 12-Month Phase 3 Study of Pasireotide in Cushing s Disease
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article A 12- Phase 3 Study of Pasireotide in Cushing s Disease Annamaria Colao, M.D., Ph.D., Stephan Petersenn, M.D., John Newell-Price,
More informationCase Report Metyrapone for Long-Term Medical Management of Cushing s Syndrome
Case Reports in Endocrinology Volume 2013, Article ID 782068, 4 pages http://dx.doi.org/10.1155/2013/782068 Case Report Metyrapone for Long-Term Medical Management of Cushing s Syndrome Andrea N. Traina,
More informationEndocrine Topic Review. Sethanant Sethakarun, MD
Endocrine Topic Review Sethanant Sethakarun, MD Definition Cushing's syndrome comprises a large group of signs and symptoms that reflect prolonged and in appropriately high exposure of tissue to glucocorticoids
More informationMANAGEMENT OF PATIENTS WITH CUSHING S DISEASE: A CANADIAN COST OF ILLNESS ANALYSIS
MANAGEMENT OF PATIENTS WITH CUSHING S DISEASE: A CANADIAN COST OF ILLNESS ANALYSIS S. Van Uum 1, M. Hurry 2, R. Petrella 1, C. Koch 2, G. Dranitsaris 3, A. Lacroix 4 1 Western University, Schulich School
More informationHigh and Low GH: an update of diagnosis and management of GH disorders
High and Low GH: an update of diagnosis and management of GH disorders Georgia Chapter-AACE 2017 Laurence Katznelson, MD Professor of Medicine and Neurosurgery Associate Dean of Graduate Medical Education
More informationPasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line
Pasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line December 2010 This technology summary is based on information available at the time of research and a limited literature
More informationRecent advances in the medical treatment of Cushing s disease Maria Fleseriu
Published: 03 March 2014 2014 Faculty of 1000 Ltd Recent advances in the medical treatment of Cushing s disease Maria Fleseriu Address: Northwest Pituitary Center, and Departments of Medicine and Neurological
More informationAldosterone synthase inhibitors. John McMurray BHF Cardiovascular Research Centre University of Glasgow
Aldosterone synthase inhibitors John McMurray BHF Cardiovascular Research Centre University of Glasgow Inhibition of aldosterone synthesis is hypothesized to be of benefit to patients with cardiovascular
More informationSponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1
Sponsor Novartis Generic Drug Name Pasireotide Therapeutic Area of Trial Cushing s disease Protocol Number CSOM230B2208E1 Title Extension to a multicenter, open-label study to assess the safety and efficacy
More informationCUSHING'S SYNDROME. Bharath University, Chrompet, Chennai, Tamil Nadu, India
TJPRC: International Journal of Nursing and Patient Safety & Care (TJPRC: IJNPSC) Vol. 1, Issue 1, Jun 2016, 57-62 TJPRC Pvt. Ltd. CUSHING'S SYNDROME R. RAMANI 1 & V. HEMAVATHY 2 1 Associate Professor,
More informationSomatotroph Pituitary Adenomas (Acromegaly) The Diagnostic Pathway (11-2K-234)
Somatotroph Pituitary Adenomas (Acromegaly) The Diagnostic Pathway (11-2K-234) Common presenting symptoms/clinical assessment: Pituitary adenomas are benign neoplasms of the pituitary gland. In patients
More informationDifferential Diagnosis of Cushing s Syndrome
Differential Diagnosis of Cushing s Syndrome Cushing s the Diagnostic Challenge Julia Kharlip, MD and Caitlin White, MD Endocrinology, Diabetes and Metabolism Perelman School of Medicine at the University
More informationCUSHING S SYNDROME. Australian Endocrine Society, May 26 th 2017
CUSHING S SYNDROME Ashley Grossman FMedSci Green-Templeton College, University of Oxford, Royal Free Hospital, London Barts and the London School of Medicine, London Australian Endocrine Society, May 26
More informationChallenging Pituitary Cases. Laurence Katznelson, MD Professor of Medicine and Neurosurgery Stanford University School of Medicine
Challenging Pituitary Cases Laurence Katznelson, MD Professor of Medicine and Neurosurgery Stanford University School of Medicine 1 34 yo male has incidental finding of large macroadenoma, with prolactin
More informationIndex. F Fatigue, 59 Food-dependent Cushing s syndrome, 286
A Abdominal red striae, 57, 58 Aberrant hormone receptors, AIMAH familial forms, 215 investigative protocols, 217 218 molecular mechanisms, 216, 217 paracrine mechanisms, 216 steroidogenesis, 212 213 in
More informationClinical Policy: Mifepristone (Korlym) Reference Number: CP.PHAR.101
Clinical Policy: (Korlym) Reference Number: CP.PHAR.101 Effective Date: 05/12 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationCUSHING S SYNDROME THE FACTS YOU NEED TO KNOW
CUSHING S SYNDROME THE FACTS YOU NEED TO KNOW Written by: Paul Margulies, MD, FACE, FACP, Medical Director, NADF. Clinical Associate Professor of Medicine, Zucker School of Medicine at Hofstra/Northwell.
More informationMineralocorticoids: aldosterone Angiotensin II/renin regulation by sympathetic tone; High potassium will stimulate and ACTH Increase in aldosterone
Disease of the Adrenals 1 Zona Glomerulosa Mineralocorticoids: aldosterone Angiotensin II/renin regulation by sympathetic tone; High potassium will stimulate and ACTH Increase in aldosterone leads to salt
More informationAdrenal Gland Disorders
1 Adrenal Gland Disorders Adrenal cortex steroid hormones (corticosteroids) 1. Glucocorticoids Regulate metabolism and blood glucose Critical to physiologic stress response 2. Mineralocorticoids Regulate
More informationCUSHING S SYNDROME AND CUSHING S DISEASE
PATIENT INFORMATION CUSHING S SYNDROME AND CUSHING S DISEASE YOUR QUESTIONS ANSWERED 2013 Update Contents What are Cushing s syndrome and Cushing s disease? What causes Cushing s syndrome and Cushing s
More informationProfessor Ian Holdaway. Endocrinologist Auckland District Health Board
Professor Ian Holdaway Endocrinologist Auckland District Health Board A land of milk and giants hormonesecreting pituitary tumours I M Holdaway, Endocrinologist, Auckland Acromegaly Prolactinomas Cushing
More informationEFFECTIVE MEDICAL THERAPY FOR CUSHING DISEASE CAN INCREASE THE SUSCEPTIBILITY TO RELATIVE HYPOCORTISOLISM
Case Report EFFECTIVE MEDICAL THERAPY FOR CUSHING DISEASE CAN INCREASE THE SUSCEPTIBILITY TO RELATIVE HYPOCORTISOLISM Kevin C.J. Yuen, MD, FRCP (UK), FACE; Jennifer U. Mercado, ARNP; Kelley Moloney, ARNP;
More informationHow to Recognize Adrenal Disease
How to Recognize Adrenal Disease CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi
More informationpharmacology sheet #9 Adrenal Steroids Mineral corticoids & Glucocorticoids
Adrenal Steroids Mineral corticoids & Glucocorticoids Extra notes : Slide 2: - All Steroids are synthesized in the adrenal gland and secreted from it, It consists of an outer cortex and an inner medulla.
More informationManaging Acromegaly: Biochemical Control with SIGNIFOR LAR (pasireotide)
Managing Acromegaly: Biochemical Control with SIGNIFOR LAR (pasireotide) INDICATION AND USAGE SIGNIFOR LAR (pasireotide) for injectable suspension is a somatostatin analog indicated for the treatment of
More informationHyperadrenocorticism or Cushing's Syndrome in Dogs
Customer Name, Street Address, City, State, Zip code Phone number, Alt. phone number, Fax number, e-mail address, web site Hyperadrenocorticism or Cushing's Syndrome in Dogs (Excessive Levels of Steroids
More informationTreating a Growing Problem: A Closer Look at Acromegaly. Lisa Nachtigall, MD (Moderator) Nicholas Tritos, MD, DSc Brooke Swearingen, MD
Treating a Growing Problem: A Closer Look at Acromegaly Lisa Nachtigall, MD (Moderator) Nicholas Tritos, MD, DSc Brooke Swearingen, MD Goal Address key challenges faced by physicians who treat acromegaly
More informationCase Report Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing s Syndrome
Case Reports in Endocrinology Volume 2016, Article ID 8453801, 5 pages http://dx.doi.org/10.1155/2016/8453801 Case Report Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing s Syndrome
More informationReview Thieme Stalla GK et al. The Adrenal Gland: Central. Exp Clin Endocrinol Diabetes 2018; 00: Cushing s Disease
Stalla GK et al. The Adrenal Gland: Central. Exp Clin Endocrinol Diabetes 2018; 00: 00 00 Cushing s Disease Authors Günter K. Stalla, Denis Ciato, Christina Dimopoulou Affiliation Department of Clinical
More informationEndocrine. Endocrine as it relates to the kidney. Sarah Elfering, MD University of Minnesota
Endocrine Sarah Elfering, MD University of Minnesota Endocrine as it relates to the kidney Parathyroid gland Vitamin D Endocrine causes of HTN Adrenal adenoma PTH Bone Kidney Intestine 1, 25 OH Vitamin
More informationPhysiology. The Hypothalamic Pituitary Adrenal Axis. Elena A Christofides, MD, FACE
Elena A Christofides, MD, FACE Endocrinology Associates, Inc Endocrinology Research Associates, Inc Physiology 2 The Hypothalamic Adrenal Axis A Complex Set of Feedback Influences* Hypothalamus releases
More information2
1 2 General % Obesity 90 Hypertension 85 Skin Plethora 70 Hirsutism/hair loss 75 Striae 50 Acne 35 Bruising/thinning 35 Musculoskeletal Osteopenia/porosis 80 Weakness 65 Neuropsych % Lability,euphoria,insomnia,
More informationLong-term treatment of Cushing s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
Endocrine (2017) 57:156 165 DOI 10.1007/s12020-017-1316-3 ORIGINAL ARTICLE Long-term treatment of Cushing s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
More informationKingdom of Bahrain Arabian Gulf University College of Medicine and Medical Sciences. Endocrinology. (Review) Year 5 Internal Medicine
Kingdom of Bahrain Arabian Gulf University College of Medicine and Medical Sciences Endocrinology (Review) Year 5 Internal Medicine Presented by: Dr. Mona Arekat Prepared by: Ali Jassim Alhashli Case (1):
More informationA review of Cushing s disease treatment by the Department of Neuroendocrinology of the Brazilian Society of Endocrinology and Metabolism
review A review of Cushing s disease treatment by the Department of Neuroendocrinology of the Brazilian Society of Endocrinology and Metabolism Márcio Carlos Machado 1, Maria Candida Barisson Vilares Fragoso
More informationAcromegaly: Management of the Patient Who Has Failed Surgery
Acromegaly: Management of the Patient Who Has Failed Surgery Minnesota/Midwest Chapter of the American Association of Clinical Endocrinologists 8 th Annual Meeting October 14, 2017 Mark E. Molitch, M.D.
More informationENDOCRINOLOGY 3. R. A. Benacka, MD, PhD, prof. Department of Pathophysiology Medical faculty, Safarik University, Košice
Academic lectures for general medicine 3rd year 2005/2006, 2013/2014 ENDOCRINOLOGY 3 R. A. Benacka, MD, PhD, prof. Department of Pathophysiology Medical faculty, Safarik University, Košice Figures and
More informationIntroduction. James W. Findling 1 Maria Fleseriu. Rosario Pivonello 5 Albert Kandra
Endocrine (216) 54:516 523 DOI 1.17/s122-16-978-6 ORIGINAL ARTICLE Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing s disease: 12-month, Phase III
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Novel approaches in hypertension Aldosterone-synthase inhibitors. Faiez Zannad Nancy, France Disclosures Dr Zannad reports receiving Speaker/consultant honoraria from
More informationCorticosteroids. Hawler Medical University College of Medicine Department of Pharmacology and Biophysics Dr.Susan Abdulkadir Farhadi MSc Pharmacology
Corticosteroids Hawler Medical University College of Medicine Department of Pharmacology and Biophysics Dr.Susan Abdulkadir Farhadi MSc Pharmacology Objectives By the end of this lecture you should be
More informationReview Article Management Strategies for Aggressive Cushing s Syndrome: From Macroadenomas to Ectopics
Journal of Oncology Volume 2012, Article ID 685213, 9 pages doi:10.1155/2012/685213 Review Article Management Strategies for Aggressive Cushing s Syndrome: From Macroadenomas to Ectopics Carlotta Pozza,
More informationBritish Journal of Medicine & Medical Research 9(1): 1-5, 2015, Article no.bjmmr ISSN:
British Journal of Medicine & Medical Research 9(1): 1-5, 2015, Article no.bjmmr.18691 ISSN: 2231-0614 SCIENCEDOMAIN international www.sciencedomain.org Cushing s Disease and High Dose Cabergoline Monotherapy:
More informationACTH-dependent Cushing s Syndrome Update AACE MI Chapter Annual Meeting September 22, Lynnette K. Nieman DEOB, NIDDK, NIH, DHHS
ACTH-dependent Cushing s Syndrome Update AACE MI Chapter Annual Meeting September 22, 2018 Lynnette K. Nieman DEOB, NIDDK, NIH, DHHS Objectives At the conclusion of this presentation, participants should
More informationChiara Simeoli. Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia Università Federico II di Napoli
Chiara Simeoli Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia Università Federico II di Napoli GC REPLACEMENT TREATMENT AN IDEAL DRUG SHOULD: normalize the standardized mortality
More informationClinical Commissioning Policy: Pegvisomant for acromegaly as a third-line treatment (adults)
Clinical Commissioning Policy: Pegvisomant for acromegaly as a third-line treatment (adults) Reference: NHS England: 16050/P NHS England INFORMATION READER BOX Directorate Medical Operations and Information
More informationCUSHING S SYNDROME. Chapter 8. Case: A 43-year-old man with delusions
Chapter 8 CUSHING S SYNDROME Case: A 43-year-old man with delusions A previously healthy 43-year-old man is brought to the emergency department for evaluation of confusion. The patient has complained to
More informationAVS and IPSS: The Basics and the Pearls
AVS and IPSS: The Basics and the Pearls William F. Young, Jr., MD, MSc Professor of Medicine Mayo Clinic College of Medicine Rochester, MN, USA 2018 Mayo Foundation for Medical Education and Research.
More informationC h a p t e r 3 8 Cushing s Syndrome : Current Concepts in Diagnosis and Management
C h a p t e r 3 8 Cushing s Syndrome : Current Concepts in Diagnosis and Management Padma S Menon Professor of Endocrinology, Seth G S Medical College & KEM Hospital, Mumbai A clinical syndrome resulting
More informationCushing s Syndrome. Diagnosis. GuidelineCentral.com. Key Points. Diagnosis
Cushing s Syndrome Consultant: Endocrine Society of Cushing s Syndrome Clinical Practice Guideline Writing Committee Key Points GuidelineCentral.com Key Points The most common cause of Cushing s syndrome
More informationAVS and IPSS: The Basics and the Pearls William F. Young, Jr., MD, MSc Professor of Medicine Mayo Clinic College of Medicine Rochester, MN, USA
AVS and IPSS: The Basics and the Pearls William F. Young, Jr., MD, MSc Professor of Medicine Mayo Clinic College of Medicine Rochester, MN, USA 2016 Mayo Foundation for Medical Education and Research.
More informationAssistant Professor of Endocrinology
Pathophysiology Of Adrenal Disorder Dr.Rezvan Salehidoost Assistant Professor of Endocrinology Pathophysiology Of Adrenal Disorder The adrenal glands lie at the superior pole of each kidney and are composed
More informationCushing s disease: current trends in treatment
Review Cushing s disease: current trends in treatment Agata Juszczak1 & Ashley B Grossman*1 Practice Points Diagnostic work-up of Cushing s disease should be performed in an experienced endocrine center
More informationDavid Henley. Sir Charles Gairdner Hospital, Nedlands WA University of Western Australia. ESA Seminar Weekend, Melbourne Vic 27 th May 2017
David Henley Sir Charles Gairdner Hospital, Nedlands WA University of Western Australia ESA Seminar Weekend, Melbourne Vic 27 th May 2017 Disclosures Received honoraria from Ipsen, Novartis, Servier, Bristol-Myers
More informationThe Work-up and Treatment of Adrenal Nodules
The Work-up and Treatment of Adrenal Nodules Lawrence Andrew Drew Shirley, MD, MS, FACS Assistant Professor of Surgical-Clinical Department of Surgery Division of Surgical Oncology The Ohio State University
More informationPharmacy Prior Authorization Somatostatin Analogs Clinical Guideline
Sandostatin LAR (octreotide) Signifor (pasireotide) Signifor LAR (pasireotide) Somatuline Depot (lanreotide) octreotide FDA Approved Indications: Acromegaly: Octreotide Injection is indicated to reduce
More informationChallenging Pituitary Cases
Challenging Pituitary Cases Sue Samson, MD, PhD, FRCPC, FACE Associate Professor of Medicine and Neurosurgery Medical Director Pituitary Center Baylor College of Medicine, Houston TX Tom Blevins, MD, FNLA,
More informationA survey of clinical practice patterns in diagnosis and management of Cushing's disease in Iran
Original Article Medical Journal of the Islamic Republic of Iran (MJIRI) Iran University of Medical Sciences A survey of clinical practice patterns in diagnosis and management of Cushing's disease in Iran
More informationAhmed Al Nahari Pediatric Endocrinology Fellow March 11,2016
Ahmed Al Nahari Pediatric Endocrinology Fellow March 11,2016 Scholar: Review the literature in an evidenced based manner to determine the difference in our clinical setting. Advocate: Develop a better
More information7/31/18. Expanding Options for the Treatment of Canine Cushing s Disease. Introduction. Cushing s in Man
Expanding Options for the Treatment of Canine Cushing s Disease David Bruyette, DVM, DACVIM Chief Medical Officer Anivive Lifescience 3750 Schaufele Rd, Suite 100 Long Beach, CA. 90808 E-mail: david@anivive.com
More information74. Hormone synthesis in the adrenal cortex. The glucocorticoids: biosynthesis, regulation, effects. Adrenal cortex is vital for life!
74. Hormone synthesis in the adrenal cortex. The glucocorticoids: biosynthesis, regulation, effects. Adrenal cortex is vital for life! 5 g each Zona glomerulosa : Mineralocorticoids ALDOSTERON Zona fasciculata:
More informationOctober 13, Surgical Nuances to Managing Cushing s Disease. Cortisol Regulation. Cushing s Syndrome Excess Cortisol. Sandeep Kunwar, M.D.
Surgical Nuances to Managing Cushing s Disease Cortisol Regulation Sandeep Kunwar, M.D. Surgical Director, California Center for Pituitary Disorders Associate Clinical Professor, University of California,
More informationTo cite this version: HAL Id: inserm
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing s disease: results from an open-ended, open-label extension trial Jochen Schopohl, Feng
More informationClinical Study The Role of Isotretinoin Therapy for Cushing s Disease: Results of a Prospective Study
International Journal of Endocrinology Volume 2016, Article ID 8173182, 9 pages http://dx.doi.org/10.1155/2016/8173182 Clinical Study The Role of Isotretinoin Therapy for Cushing s Disease: Results of
More informationACUTE SEVERE CUSHING SYNDROME: NOT ALWAYS ECTOPIC ACTH SYNDROME
Case Report ACUTE SEVERE CUSHING SYNDROME: NOT ALWAYS ECTOPIC ACTH SYNDROME Carlos Tavares Bello, MD 1 ; Inês Gil, MD 2 ; Filipa Alves Serra, MD 3 ; João Sequeira Duarte 1 ABSTRACT Objective: Cushing syndrome
More informationGalvus the most comprehensively studied DPP-4 inhibitor
Galvus the most comprehensively studied DPP-4 inhibitor! >7 000 patients enrolled in clinical studies! >4 00 patients exposed to Galvus >1 300 patients exposed 2 weeks >300 patients exposed for 104 weeks!
More informationUpdates in primary hyperaldosteronism and the rule
Updates in primary hyperaldosteronism and the 20-50 rule I. David Weiner, M.D. Professor of Medicine and Physiology and Functional Genomics University of Florida College of Medicine and NF/SGVHS The 20-50
More informationLate-night salivary cortisol (LNSC) is a measure of nadir
ORIGINAL ARTICLE Accuracy of Late-Night Salivary Cortisol in Evaluating Postoperative Remission and in Cushing s Disease Fatemeh G. Amlashi, Brooke Swearingen, Alexander T. Faje, Lisa B. Nachtigall, Karen
More informationStudies on the diagnosis and treatment of canine Cushing s disease
Studies on the diagnosis and treatment of canine Cushing s disease Summary of the Doctoral Thesis Asaka Sato (Supervised by Professor Yasushi Hara) Graduate School of Veterinary Medicine and Life Science
More informationAdrenal Disorders for the USMLE, Step One: Abnormalities of the Fasciculata: Hypercortisolism
Adrenal Disorders for the USMLE, Step One: Abnormalities of the Fasciculata: Hypercortisolism Howard Sachs, MD Patients Course, 2017 Associate Professor of Clinical Medicine UMass Medical School Adrenal
More informationCushing it uphill: a Sisyphean case
Sunita MC De Sousa Ann I McCormack St Vincent s Hospital, Sydney ESA Clinical Weekend 2014 Cushing it uphill: a Sisyphean case None Declarations of interests 27 F, engaged to be married Weight gain, fatigue,
More informationSubject Index. hypothalamic-pituitary-adrenal axis 158. Atherosclerosis, ghrelin role AVP, see Arginine vasopressin.
Subject Index Acromegaly, somatostatin analog therapy dopamine agonist combination therapy 132 efficacy 132, 133 overview 130, 131 receptor subtype response 131, 132 SOM30 studies 131, 132 ACTH, see Adrenocorticotropic
More informationCortisol (serum, plasma)
Cortisol (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Cortisol 1.2 Alternative names Hydrocortisone, 11β; 17, 21 trihydroxypregn 4 ene 3,20 dione 1.3 NMLC code 1.4 Description
More informationTreatment of Cushing s Syndrome: An Endocrine Society Clinical Practice Guideline
SPECIAL FEATURE Clinical Practice Guideline Treatment of Cushing s Syndrome: An Endocrine Society Clinical Practice Guideline Lynnette K. Nieman (chair), Beverly M. K. Biller, James W. Findling, M. Hassan
More informationMANAGEMENT OF HYPERGLYCEMIA IN A PATIENT WITH ACROMEGALY TREATED WITH PASIREOTIDE LAR: A CASE STUDY
Case Report MANAGEMENT OF HYPERGLYCEMIA IN A PATIENT WITH ACROMEGALY TREATED WITH PASIREOTIDE LAR: A CASE STUDY Murray B. Gordon, MD, FACE; Kellie L. Spiller, MS ABSTRACT Submitted for publication July
More informationAdrenal gland And Pancreas
Adrenal gland And Pancreas Structure Cortex Glucocorticoids Effects Control of secretion Mineralocorticoids Effects Control of secretion Sex steroids Medulla Catecholamines Adrenal cortex 80% of an adrenal
More informationArlt W et al.: Steroid Metabolome analysis reveals prevalent glucocorticoid excess in
Figure S1: Comparison of 24-h urinary steroid metabolite excretion in 162 healthy controls and 174 patients with. Panel A, tetrahydroaldosterone; Panel B, cortisol; Panel C, total glucocorticoid metabolites.
More informationThe endocrine system is complex and sometimes poorly understood.
1 CE Credit Testing the Endocrine System for Adrenal Disorders and Diabetes Mellitus: It Is All About Signaling Hormones! David Liss, BA, RVT, VTS (ECC) Platt College Alhambra, California For more information,
More informationWhere in the adrenal cortex is cortisol produced? How do glucocorticoids inhibit prostaglandin production?
CASE 35 A 36-year-old woman presents to her gynecologist with complaints of amenorrhea and hirsutism. She has also noticed an increase in her weight (especially in the trunk region) and easy fatigability.
More informationPathophysiology of Adrenal Disorders
Pathophysiology of Adrenal Disorders PHCL 415 Hadeel Alkofide April 2010 Some slides adapted from Rania Aljizani MSc 1 Learning Objectives Describe the roles of the various zones of the adrenal cortex
More informationMILD HYPERCORTISOLISM DUE TO ADRENAL ADENOMA: IS IT REALLY SUBCLINICAL?
MILD HYPERCORTISOLISM DUE TO ADRENAL ADENOMA: IS IT REALLY SUBCLINICAL? Alice C. Levine, MD Professor of Medicine Division of Endocrinology, Diabetes and Bone Diseases Georgia-AACE 2017 Annual Meeting
More informationCushing's disease, Cushing's syndrome
Greenville Veterinary Clinic LLC 409 E. Jamestown Rd. Greenville, PA 16125 (724) 588-5260 Canine hyperadrenocorticism Cushing's disease, Cushing's syndrome AffectedAnimals: Although dogs of almost every
More information